Saniona signs million-dollar deal with US-based company
Danish biotech Saniona has signed a deal worth up to USD 30 million with a US-based corporation to develop drugs against neurological disorders. Saniona’s CFO calls it a stroke of luck for investors.
BY STEFAN SINGH KAILAY
There was a spot of good news for Saniona’s investors this week, says the Danish-based biotech’s CFO, Thomas Feldthus, about the new deal his company signed with US-based Upsher-Smith Wednesday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Pfizer cancels partnership with Danish biotech
For abonnenter
Biotech initiates partnership search immediately
For abonnenter
“I‘m certainly not bitter, but maybe a bit disappointed”
For abonnenter
